Which of the following is a therapuetic drug class for olanzapine?

A. Olanzapine does not possess pharmacological activity within the medullary cough center or peripheral stretch receptors. It lacks the properties of an antitussive agent such as benzonatate or codeine. It is not indicated for the suppression of a cough reflex. B. This compound does not function as an antiarrhythmic by modulating cardiac ion channels. It lacks the specific electrophysiological effects required for classes 1 through 4 of the Vaughan Williams classification. It is not used to treat atrial or ventricular arrhythmias. C. Olanzapine is a second-generation atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. It is clinically indicated for the treatment of schizophrenia and bipolar 1 disorder. This mechanism effectively modulates mesolimbic and mesocortical dopaminergic pathways in the brain. D. Although olanzapine may reduce agitation associated with psychiatric disorders, it is not primarily classified as an anxiolytic. It lacks the specific benzodiazepine or buspirone-like mechanisms typically utilized for generalized anxiety disorder. Its primary therapeutic designation remains within the antipsychotic class.